<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776503</url>
  </required_header>
  <id_info>
    <org_study_id>GFM VOR 2007-01</org_study_id>
    <nct_id>NCT00776503</nct_id>
  </id_info>
  <brief_title>Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia</brief_title>
  <acronym>GFMVOR2007</acronym>
  <official_title>A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated duration and schedule of oral&#xD;
      VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High&#xD;
      risk myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, non-randomized, Phase I/II study. Patients will be&#xD;
      treated either with arm A or B dosing schedules which contain increasing durations of&#xD;
      exposure to vorinostat. LD Ara-C will be administered once daily, subcutaneously(SC), at 10&#xD;
      mg/m² in Cycle 1 and escalated to 20 mg/m² daily in Cycle 2 and above for 14 out of 28 days.&#xD;
      Oral vorinostat will be administered as 400 mg, once daily either sequentially(Arm A) or&#xD;
      concurrently (Arm B) with LD Ara-C in Dose Level #1 for 7 days, Dose Level #2 for 10 days, or&#xD;
      Dose Level #3 for 14 days out of each 28-day cycle. Patients who do not have disease&#xD;
      progression and who continue to meet eligibility criteria may receive up to 3 additional&#xD;
      28-day cycles of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Maximum tolerated dose of the association</measure>
    <time_frame>After 1 cycle of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the clinical activity of this association</measure>
    <time_frame>after 3 cycles of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VORINOSTAT</intervention_name>
    <description>vorinostat; 400mg once daily; increasing duration (7-10-14 days)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>SAHA</other_name>
    <other_name>ZOLINZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all of the following criteria to participate in the study:&#xD;
&#xD;
               1. Patient has MDS including the following FAB sub-types: refractory anemia with&#xD;
                  blast excess (RAEB) ,transformed refractory anemia with blast excess (RAEB-t) and&#xD;
                  non proliferative Chronic MyeloMonocytic Leukemias (WBC below 13G/l).&#xD;
&#xD;
               2. Patient has a IPSS score &gt; 1. 5 (INT-2 and high risk categories).&#xD;
&#xD;
               3. Patient must have been previously treated with demethylating agents (including&#xD;
                  Azacitidine and Decitabine) and :&#xD;
&#xD;
                    1. failed to respond or&#xD;
&#xD;
                    2. progress after treatment.&#xD;
&#xD;
               4. Patient is male or female, and ≥ 18 years of age on day of signing informed&#xD;
                  consent.&#xD;
&#xD;
               5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
                  (See Appendix 6.1).&#xD;
&#xD;
               6. Patient has recovered from toxicities due to prior therapy (less than grade 2)&#xD;
                  except for cytopenia&#xD;
&#xD;
               7. Patient must have adequate organ function as indicated by the following&#xD;
                  laboratory values: serum creatinine &lt;2mg/dl; total bilirubin &lt;2,5ULN; AST&lt;2,5ULN,&#xD;
                  ALT&lt;2,5ULN, PAL&lt;5ULN&#xD;
&#xD;
               8. Patient is known to not be refractory to platelet transfusions.&#xD;
&#xD;
               9. Female patient of childbearing potential has a negative serum pregnancy test&#xD;
                  (β-hCG) within 72 hours prior to receiving the first dose of vorinostat and or&#xD;
                  Ara-C . Female patient is not actively breastfeeding at the time of study entry.&#xD;
&#xD;
              10. Female patient is either post-menopausal, free from menses for &gt; 2 years,&#xD;
                  surgically sterilized or willing to use 2 adequate barrier methods of&#xD;
                  contraception to prevent pregnancy or agrees to abstain from becoming pregnant&#xD;
                  throughout the study, starting with Visit 1.&#xD;
&#xD;
              11. Male patient agrees to use an adequate method of contraception for the duration&#xD;
                  of the study. Men should be advised not to father a child while receiving&#xD;
                  vorinostat and for 1 month post study.&#xD;
&#xD;
              12. Patient is available for periodic blood sampling, study related assessments, and&#xD;
                  appropriate clinical management at the treating institution for the duration of&#xD;
                  the study.&#xD;
&#xD;
              13. Patient has the ability to understand and willingness to sign an informed consent&#xD;
                  form indicating the investigational nature of the study.&#xD;
&#xD;
              14. Patient is able to swallow capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient had prior treatment with an HDAC inhibitor (e.g., depsipeptide or NSC-630176,&#xD;
             MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have&#xD;
             received compounds with HDAC inhibitor-like activity, such as valproic acid, as&#xD;
             anti-tumor therapy should not enroll in this study. Patients who have received such&#xD;
             compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a&#xD;
             30-day washout period.&#xD;
&#xD;
          2. Patient has been previously treated with low dose (20 mg/m2 SC daily) Ara-C for MDS&#xD;
             within 3 months of beginning this study.&#xD;
&#xD;
          3. Patient has active and uncontrolled infection&#xD;
&#xD;
          4. Patient has uncontrolled intercurrent illness or circumstances that could limit&#xD;
             compliance with the study, including but not limited to the following: symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia,&#xD;
             pancreatitis, or psychiatric or social conditions that may interfere with patient&#xD;
             compliance.&#xD;
&#xD;
          5. Patient is currently participating or has participated in a study with an&#xD;
             investigational compound or device within 30 days of initial dosing with study drug.&#xD;
&#xD;
          6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related&#xD;
             malignancy.&#xD;
&#xD;
          7. Patient has clinically active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          8. Patient has a known allergy or hypersensitivity to any component of vorinostat or&#xD;
             Ara-C.&#xD;
&#xD;
          9. Patient with a &quot;currently active&quot; second malignancy, other than nonmelanoma skin&#xD;
             cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not&#xD;
             considered to have a &quot;currently active&quot; malignancy if they have completed therapy for&#xD;
             a prior malignancy, are disease free from prior malignancies for &gt;5 years or are&#xD;
             considered by their physician to be at less than 30% risk of relapse.&#xD;
&#xD;
         10. Patient has received growth factors such as epoetin alfa (EPO) or granulocyte&#xD;
             colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low&#xD;
             dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic&#xD;
             treatment, an interval of 3 months is required.&#xD;
&#xD;
         11. Patient is on any systemic steroids that have not been stabilized to the equivalent of&#xD;
             ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs&#xD;
&#xD;
         12. Patients with clinical evidence of CNS leukemia.&#xD;
&#xD;
         13. Patient has a history of GI surgery or other procedures that might interfere with the&#xD;
             absorption or swallowing of the study drugs.&#xD;
&#xD;
         14. Patient is unable to take and/or tolerate oral medications on a continuous basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas PREBET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myelodysplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert VEY, MD</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Francophone des Myelodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Durance</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy-pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hôpital Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Heriot, dpt Hématologie Clinique</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital de l'Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Bequerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital Haute Pierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>40031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epigenetic</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

